Trial Profile
Phase Ib/IIa, Escalating Dose, Single Blind, Clinical Trial to Assess the Safety of the i.v Administration of Allogeneic Adipose-derived Mesenchymal Cells (eASCs) to Refractory Rheumatoid Arthritis (RA) Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Dec 2023
Price :
$35
*
At a glance
- Drugs Cx 611 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors TiGenix
- 07 Jun 2016 Results published in the Annals of the Rheumatic Diseases
- 10 Sep 2013 Results will be presented at a plenary session at the the Annual Meeting of the American College of Rheumatology (ACR) in October 2013.
- 06 May 2013 6-month safety data and interim efficacy from phase IIa reported in a TiGenix media release.